文献速递脊柱关节炎

乌帕替尼对银屑病关节炎患者附着点炎的影响:SELECT-PsA 1和2试验的事后分析

Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该事后分析基于SELECT-PsA 1和2两项3期试验,评估乌帕替尼15 mg每日一次对银屑病关节炎患者附着点炎的作用。结果显示,与安慰剂相比,乌帕替尼15 mg在24周时附着点炎消退率更高(LEI:59.8% vs 38.0%;SPARCC指数:50.6% vs 31.5%),且改善在56周内维持。

要点

  • 乌帕替尼15 mg每日一次在24周时附着点炎消退率高于安慰剂(LEEDS附着点炎指数:59.8% vs 38.0%;SPARCC指数:50.6% vs 31.5%)。
  • 乌帕替尼15 mg在12周治疗后即观察到附着点炎改善,且改善维持至56周。
  • 基线无附着点炎(LEI=0)且接受乌帕替尼15 mg的患者中,超过90%在56周时仍无附着点炎;基线有附着点炎且在24周达到消退(LEI=0)的患者中,超过80%在56周时未复发。

核心结论

  • 乌帕替尼15 mg每日一次与附着点炎的全面改善相关,治疗12周后即可观察到改善。
  • 乌帕替尼15 mg治疗与附着点炎消退后维持无附着点炎状态及预防新发附着点炎相关。

研究设计与样本

  • SELECT-PsA 1和2两项3期试验的事后分析,纳入对一种或以上非生物制剂改善病情抗风湿药应答不足或不耐受(SELECT-PsA 1)或对一种或以上生物制剂改善病情抗风湿药应答不足或不耐受(SELECT-PsA 2)的银屑病关节炎患者。
  • 患者接受乌帕替尼15 mg每日一次、阿达木单抗40 mg隔周一次或安慰剂(第0-24周),安慰剂组在第24周后换用乌帕替尼15 mg。
  • 分析纳入接受乌帕替尼15 mg的639例患者和接受安慰剂的635例患者(其中317例从安慰剂换用乌帕替尼15 mg)的数据。
  • 使用Leeds附着点炎指数(LEI)和加拿大脊柱关节炎研究联盟(SPARCC)指数评估附着点炎改善、消退、消退维持及预防新发,随访至第56周。

主要发现

  • 第24周时,乌帕替尼15 mg组附着点炎消退率高于安慰剂组(LEI:59.8% vs 38.0%;SPARCC指数:50.6% vs 31.5%)。
  • 第24周时,乌帕替尼15 mg组LEI改善程度大于安慰剂组(-1.7 vs -1.0),SPARCC指数改善程度也大于安慰剂组(-3.4 vs -1.9)。
  • 改善维持至第56周,且在乌帕替尼15 mg治疗12周后即观察到改善。
  • 基线无附着点炎(LEI=0)且接受乌帕替尼15 mg的患者中,超过90%在第56周时无附着点炎。
  • 基线有附着点炎且在24周达到消退(LEI=0)的患者中,乌帕替尼15 mg在超过80%的患者中预防了第56周时附着点炎复发。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To characterize the effect of upadacitinib 15 mg once daily (UPA15) on enthesitis in patients with PsA from the SELECT-PsA Phase 3 trials. METHODS: Patients with an inadequate response/intolerance to one or more non-biologic DMARD (SELECT-PsA 1) or one or more biologic DMARD (SELECT-PsA 2) received UPA15, adalimumab 40 mg every other week or placebo (weeks 0-24) switched to UPA15 (week 24 onward). The Leeds Enthesitis Index (LEI) and Spondyloarthritis Research Consortium of Canada (SPARCC) index were used to assess improvement in enthesitis, enthesitis resolution, maintenance of enthesitis resolution and protection from enthesitis development through week 56. RESULTS: Data from 639 patients receiving UPA15 and 635 patients receiving placebo (including 317 patients who switched from placebo to UPA15) were analysed. UPA15 led to higher rates of enthesitis resolution vs placebo at week 24 (LEI: 59.8% vs 38.0%; SPARCC index: 50.6% vs 31.5%, respectively) and greater improvements in the LEI (-1.7 vs -1.0) and SPARCC index (-3.4 vs -1.9); improvements were maintained through week 56. Improvements were observed after 12 weeks of UPA15 treatment. Over 90% of patients without enthesitis (LEI = 0) at baseline receiving UPA15 were enthesitis-free at week 56, and UPA15 prevented recurrence of enthesitis at week 56 in >80% of patients with enthesitis at baseline who achieved resolution (LEI = 0) at week 24. CONCLUSIONS: UPA15 is associated with a comprehensive improvement in enthesitis, with improvements observed after 12 weeks of treatment. Additionally, treatment with UPA15 was associated with maintaining an enthesitis-free state after resolution and protection against new-onset enthesitis. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT03104400 (SELECT-PsA 1) and NCT03104374 (SELECT-PsA 2).

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Cantini F, Marchesoni A, Novelli L, et al. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials. Rheumatology (Oxford). 2024. PMID: 38331400. doi:10.1093/rheumatology/keae057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。